Anti-angiogenesis and diffuse large B-cell lymphoma: a new treatment opportunity?
Portlock
C
C
Department of Medicine, Memorial Sloan Kettering, Cancer Center, New York, NY 10021, USA. portlocc@mskcc.org
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000068258:Bevacizumab; D003520:Cyclophosphamide / Q000627:therapeutic use; D016207:Cytokines / Q000378:metabolism; D004317:Doxorubicin / Q000627:therapeutic use; D006801:Humans; D016393:Lymphoma, B-Cell / Q000188:drug therapy* / Q000473:pathology*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000473:pathology*; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis; D012306:Risk; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism; D014750:Vincristine / Q000627:therapeutic use
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D016207:Cytokines; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone